Zymeworks enters its first ZymeLink antibody-drug conjugate platform licensing agreement with Iconic Therapeutics
Zymeworks has entered into a licensing agreement that grants Iconic Therapeutics non-exclusive rights to Zymeworks’ proprietary ZymeLink antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.